(BLLN) BillionToOne, Inc. Business Model Canvas Research

Health insurers and reimbursement partners are central to BillionToOne, Inc. because they decide whether clinical tests are covered and paid for; prior authorization and claims handling shape adoption and patient access. Even strong test demand can stall if reimbursement is slow, inconsistent, or denied.

• Coverage drives test uptake.
• Prior auth slows or speeds sales.
• Claims approval supports cash flow.

Research institutions and biopharma partners help BillionToOne validate assays, expand biomarkers, and generate the clinical evidence needed to grow its test menu. For a molecular diagnostics platform that has already raised more than $300 million in disclosed funding, these studies are key to moving from single-use tests to broader clinical adoption.

• Validate assays with external labs
• Extend into new clinical uses
• Strengthen evidence for adoption

BillionToOne, Inc. depends on quality and regulatory operations to keep diagnostic results reproducible, traceable, and clinically reliable under CLIA and CAP controls. In a regulated molecular diagnostics business, these checks are not back office work; they are what lets each assay support patient care.

• Controls reproducibility
• Maintains traceability
• Supports clinical reliability
• Meets lab compliance rules

This is the core operating layer behind every test run.

Commercial and medical affairs support turns awareness into orders: sales teams and medical specialists train providers on test use, guide ordering workflows, and explain the evidence behind results. For BillionToOne, this matters because recurring adoption in prenatal and oncology care depends on trust, and the company has scaled with over 1 million patient samples tested.

• Educate providers on test use
• Support ordering and billing flow
• Share evidence that drives repeats

BillionToOne, Inc. depends on specialized scientific and laboratory talent in molecular biology, genomics, and diagnostics to design assays, validate tests, and prepare clinical reports. This team also drives platform innovation, which matters in diagnostics where accuracy and turnaround time shape adoption.

• Assay design and validation
• Clinical reporting expertise
• Platform innovation support

BillionToOne, Inc.’s clinical data and biomarker knowledge turn each added test into a stronger asset: more samples improve assay performance, sharpen result interpretation, and help detect new genetic and methylation signals. As the test base grows, the data flywheel makes the platform harder to copy and more useful in new use cases.

• More tests improve assay accuracy.
• Biomarkers broaden signal detection.
• Data value rises with scale.

Northstar Response uses methylation signals to track cancer progression over time, so BillionToOne, Inc. gives clinicians a dynamic disease view instead of a one-time snapshot. That makes repeat testing the value: the same assay can support ongoing response checks, treatment changes, and earlier signs of change.

• Tracks disease over time
• Uses methylation as the signal
• Supports ongoing response monitoring

BillionToOne, Inc. counts individual DNA molecules, which lifts analytical precision and improves sensitivity versus less exact methods. That matters clinically: its UNITY carrier screen has reported 99.9% sensitivity and 99.9% specificity, showing how molecule-level measurement supports accurate results.

• Counts single DNA molecules
• Higher sensitivity, fewer misses
• Precision drives clinical value

BillionToOne, Inc. uses reimbursement assistance to cut claim friction for providers and patients, which matters because diagnostics adoption often stalls when billing is unclear. By helping with coverage checks, prior auth, and claims support, the Company makes testing easier to order and more accessible in routine care.

• Reduces billing friction
• Supports coverage guidance
• Improves test access

BillionToOne, Inc. uses clinical education and training to help providers understand test indications, limits, and proper assay selection, which lowers misuse risk and supports consistent ordering. Training also builds confidence in the platform, especially when assays have different use cases and interpretation rules.

• Clarifies when each assay fits
• Explains key test limitations
• Supports correct clinical ordering
• Builds provider trust in results

Referral networks let BillionToOne, Inc. reach patients through OB-GYN and oncology specialists, so one ordering doctor can drive repeat prenatal and cancer test volume without direct consumer marketing. This keeps customer acquisition costs low and fits a lab model where clinical trust matters more than ads.

• Specialists route most orders.
• Boosts prenatal and oncology tests.
• Expands reach with low CAC.

Professional education and conferences help BillionToOne, Inc. build trust fast in a proof-heavy diagnostics market. Big medical meetings, like ASCO with about 40,000 attendees in 2025, give the Company direct access to clinicians who need clear data before they adopt a new test.

• Builds credibility with KOLs
• Explains test performance clearly
• Drives physician adoption

Hospitals and integrated health systems are high-volume buyers and test routers for BillionToOne, Inc. They can standardize access across many clinicians, and their procurement choices can drive adoption across roughly 6,120 U.S. hospitals.

• High-volume test routing
• Standardized access across clinicians
• Strong procurement influence

Pregnant patients and cancer patients are the end users who feel BillionToOne, Inc.’s clinical benefit first: noninvasive testing plus clearer risk data. Demand is usually routed through physician orders, and the addressable U.S. pool is large, with about 3.6 million births a year and roughly 2.0 million new cancer cases annually.

• Noninvasive sampling matters most.
• Clearer risk info drives decisions.
• Physicians usually place the order.

BillionToOne, Inc. must fund CLIA/CAP compliance, document control, and QC across every test run; CLIA inspections recur every 2 years, and FDA QMSR takes effect on Feb. 2, 2026. That makes regulatory and quality systems a fixed overhead, but they are what make results defensible.

• Ongoing compliance costs stay high.

• Quality systems reduce test risk.

• Defensible results support reimbursement.

Bioinformatics and IT infrastructure is a recurring cost for BillionToOne, Inc. Every test needs data analysis, report generation, secure storage, and compute-heavy workflows; even small gains matter when cloud and software costs scale with sample volume. In precision diagnostics, the back end is part of the product.

• Per-test analysis and reporting
• Secure storage for patient data
• Recurring cloud and software spend

For high-throughput molecular testing, the IT stack must stay fast, compliant, and auditable, so infrastructure costs sit in operating expense, not one-off capex.

BillionToOne, Inc. relies on insurance reimbursement collections for diagnostic revenue, so each payer claim drives realized cash and timing. Coverage approval is the key gate: when tests are covered, collections are faster and more complete; when they are denied or delayed, revenue and cash conversion slip.

• Claims drive diagnostic cash receipts.
• Coverage rules shape realized revenue.
• Reimbursement is the core monetization path.

Enterprise and institutional contracts give BillionToOne, Inc. negotiated test volumes from health systems and large provider groups, which makes ordering more predictable and helps drive broader use across sites. These deals can sit alongside per-test billing, so they add recurring demand without replacing fee-for-service revenue.

• Negotiated volume improves ordering visibility.
• Large provider groups speed adoption across networks.
• Per-test billing still supports unit economics.